This content is in French.
Breast cancer: circulating tumor DNA, a key biomarker to anticipate relapse
3 avril 2026
By Elodie Vaz | Published on April 3, 2026 | 3 min readBreast cancer remains the most common cancer among women worldwide. Despite major therapeutic advances, particularly in early-stage disease, the risk of recurrence remains a central challenge in patient management. This risk varies according to tumor subtypes, especially in aggressive forms such as triple-negative or hormone receptor-negative
By Elodie Vaz | Published on April 3, 2026 | 3 min read
Breast cancer remains the most common cancer among women worldwide. Despite major therapeutic advances, particularly in early-stage disease, the risk of recurrence remains a central challenge in patient management. This risk varies according to tumor subtypes, especially in aggressive forms such as triple-negative or hormone receptor-negative (HR−) cancers, which are often less responsive to conventional treatments.
Breast cancer remains the most common cancer among women worldwide. Despite major therapeutic advances, particularly in early-stage disease, the risk of recurrence remains a central challenge in patient management. This risk varies according to tumor subtypes, especially in aggressive forms such as triple-negative or hormone receptor-negative (HR−) cancers, which are often less responsive to conventional treatments.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Agostinetto E. Tumor DNA circulating in patients’ blood after pre-surgery treatments predicts whether breast cancer will return. EurekAlert! 2026 Mar 26.
View the source
